ERBB2 and breast cancer: By incorporating and illustrating important prognostic factors, physicians used nomograms to accurately estimate the prognosis of patients in time.[8] In this study, the female patients suffering from non-metastatic HER2 positive breast cancer were analyzed on basis of the Surveillance, Epidemiology, and End Results, US = United States (SEER) Program, including the clinicopathological characteristics and prognostic elements.